The stock market started this week off the same way it did last week -- with a pullback stemming largely from earnings-related announcements. As of 10:50 a.m. EDT, the Dow Jones Industrials (DJINDICES: ^DJI ) has fallen by 59 points, or 0.4%, while other major benchmarks are also moderately lower. Yet behind the scenes, another piece of discouraging news could have an even bigger impact on the Dow -- not just today, but in the long term as well.
On one hand, the obvious negative news for the Dow came from Caterpillar (NYSE: CAT ) , which announced lower profit, reduced capital expenditures, and guidance for future earnings that came in at the lower end of its previous range. In particular, mining-equipment sales were a sore spot for the company, as falling prices for commodities have left miners in a much more precarious financial position that won't support as many large equipment purchases. Yet with all the news from China and elsewhere in recent months pointing toward a slowdown in industrial activity, Caterpillar's news wasn't surprising, even though the stock dropped nearly 1% after initially posting gains near the open.
Hot Restaurant Stocks To Buy Right Now: Plug Power Inc.(PLUG)
Plug Power Inc., an alternative energy technology provider, involves in the design, development, commercialization, and manufacture of fuel cell systems for the industrial off-road markets and stationary power markets worldwide. It develops and sells a range of fuel cell systems comprising hydrogen-fueled Proton Exchange Membrane (PEM) systems. The company?s product line includes PEM GenDrive power unit for sale on commercial terms for industrial off-road consisting of forklift or material handling applications, with a focus on multi-shift high volume manufacturing and high throughput distribution sites. It sells its products to business, industrial, and government customers through direct product sales force, original equipment manufacturers, and their dealer networks. The company was founded in 1997 and is headquartered in Latham, New York.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Tuesday, industrials shares were relative leaders, up on the day by about 1.61 percent. Top gainers in the sector included Plug Power (NASDAQ: PLUG) and Maxwell Technologies (NASDAQ: MXWL). - [By Paul Ausick]
The most heavily traded Nasdaq stock today is Plug Power Inc. (NASDAQ: PLUG). The fuel cell maker has been riding a wave of buying based on its deal with Wal-Mart Stores Inc. (NYSE: WMT). Today, however, competitor FuelCell Energy Inc. (NASDAQ: FCEL) announced an increase in a federal contract Plug Power is getting a big coattail effect. Shares are set to close up 29.89% at $8.26 in a 52-week range of $0.15 to $8.30 (a new 52-week high today). Share volume was approaching 5-times more than the daily average of around 26 million shares traded.
Top 5 Sliver Companies For 2014: Calwest Bancorp (CALW)
CalWest Bancorp owns South County Bank, National Association. The Company is the holding company for South County Bank N.A. South County Bank operates in four divisions: business solutions, professional division, personal services and online banking. Business solutions are engaged in deposit services, cash management solutions and loan services. Professional division is engaged in physicians, dentists, veterinarians, attorneys and certified public accountants. Personal services include deposit services and loan services. Online banking includes personal login, cash management login, cash management demos and user resources.
Business solutions
Deposit services include analysis checking, unlimited checking, interest checking, money market savings, sweep accounts, zero balance accounting, payroll services and merchant card processing. Cash management services include eCorp online banking, remote deposit, electronic payments, positive pay, mobile banking, cash vault and armored transport. Its loan services include business lines of credit, commercial term loans, commercial real estate loans, equipment loans, SBA financing, construction loans and accounts receivable financing.
Professional division
Veterinarians provide deposit services, cash management services and lending services. Attorneys and certified public accountants also include deposit services, cash management services and lending services
Personal services
Deposit services include online banking, checking, saving, money market, certified deposit and retirement accounts. Its loan services include overdraft protection, home equity lines and vehicle financing.
Advisors' Opinion:- [By CRWE]
Today, CALW remains (0.00%) +0.000 at $.370 thus far (ref. google finance 10:58AM EDT July 24, 2013).
CalWest Bancorp previously reported the consolidated financial results for the six months ended June 30, 2013. Significant items for the period ending June 30, 2013 include:
Quarterly net income of $50,000, compared to the previous quarter profit of $12,000;
No additional loan loss provision required; resulting in the allowance for loan loss (ALL) ratio decreasing slightly from 6.20% to 5.95%;
Total assets were flat at $144 million, with new business offsetting run-off;
Non-performing loans reduced significantly in 2013 by 41% quarter-over-quarter; and are down $1.9 million from a year ago;
Non-interest bearing deposits maintained at 35% of total deposits, helping reduce the Bank�� cost-of-deposits to 0.40% from 0.48% a year ago;
The increase in Net Interest Income offset the reduction in Non-Interest Income as increased focus is placed on core earnings;
Non-interest expenses continue to improve, decreasing 2% quarter-over-quartee
Top 5 Sliver Companies For 2014: Roma Financial Corporation(ROMA)
Roma Financial Corporation operates as a holding company for Roma Bank and RomAsia Bank that provide traditional retail banking services primarily in New Jersey. The company offers current deposit products, including checking and savings accounts, money market, certificates of deposit accounts, and individual retirement accounts. It also provides one-to four-family residential mortgage loans; multi-family and commercial mortgage loans; construction loans; commercial business loans; and consumer loans comprising home equity loans and lines of credit. In addition, the company sells title insurance; performs title searches; and provides real estate settlement and closing services. It operates 23 branch offices in Mercer, Burlington, Camden, and Ocean Counties, New Jersey; and 2 branches in Monmouth Junction and Edison, New Jersey. The company was founded in 1920 and is headquartered in Robbinsville, New Jersey.
Advisors' Opinion:- [By Tim Melvin]
He also pointed out that the approaching completion of Roma Financial (ROMA) and Investors Bancorp (ISBC) has some interesting implications for bank stock investors. Both are mutual holding companies, and the newly formed bank is expected to complete the process and do a second-step conversion offering. That will be a fairly large deal, much larger than most second-step offerings, as the combined banks should be somewhere around $3 billion in market cap. There will be larger investment banks involved, complete with road shows and institutional meetings to promote the deal. The attention could well cause a revaluation of the mutual holding company and converted thrift sector of the banking market.
Top 5 Sliver Companies For 2014: Rexahn Pharmaceuticals Inc (RNN)
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.
Archexin
Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.
Serdaxin
Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.
Zoraxel
Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.
The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.
Advisors' Opinion:- [By James E. Brumley]
If you were lucky enough to step into Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) when your truly suggested it was a budding buy back on December 23rd, then congratulations - you're now up a little more than 60% (assuming you bought into RNN after the break above a key resistance line on the 27th). Now get out. Instead, use your profits from the Rexahn to take on a stake in GTx, Inc. (NASDAQ:GTXI). No, GTXI may not look like much at first, but when you take a step back and look at a chart of GTx, Inc. through a longer-term lens, the upside potential becomes clear.
- [By John Udovich]
So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:
- [By James E. Brumley]
At first glance, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) doesn't look like anything particularly trade-worthy. The stock's now where it was in late October, and where it was in late September, and even where it was in late June. In other words, though RNN has been much higher and much lower than its current price of $0.46 over the course of the past several months, it doesn't look like it's going anywhere - on a net basis - anytime.
- [By James E. Brumley]
With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.
No comments:
Post a Comment